Xilio Q1 net loss $9.5M; cash $150.3M; XTX501 IND planned mid-2026

Xilio Therapeutics, Inc.

2026-Q1 EPS reported -$0.58 revenue$12,648,000

Cash and cash equivalents $150.3M at Mar 31, 2026 (vs $137.5M Dec 31, 2025); runway into early 2028.
Net loss $9.5M vs $13.3M YoY; collaboration revenue $12.6M (up from $2.9M); R&D $19.8M (up from $8.3M).
Achieved $6.0M development milestone under AbbVie collaboration (Q2 2026).
XTX501 IND submission planned mid-2026; Phase 1 start H2 2026; initial data H2 2027.
Appointed Cheryl R. Blanchard, Ph.D. to board of directors (April 2026).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xilio Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $12.6 million.

Period: the first quarter ended March 31, 2026
Revenue: $12.6 million
Result: reported results

Exact text from the filing

Collaboration and license revenue was $12.6 million for the quarter ended March 31, 2026, compared to $2.9 million for the quarter ended March 31, 2025.

View on SEC.gov

571 earnings releases filed in the last 30 days. Browse all earnings releases →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-218194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.